Rifampin Capsules Recall: Incomplete Stability Studies Due to Manufacturer Closure
Akorn Inc. is recalling all lots of Rifampin Capsules USP 300 mg distributed nationwide due to incomplete stability studies. The manufacturer ceased operations and could not continue required testing.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves a prescription drug with unconfirmed stability due to incomplete testing. While no illnesses or injuries have been reported and the hazard is theoretical, this represents a risk-of-harm product where stability confirmation is critical. The theoretical nature of the hazard and absence of reported harm place this at the maximum allowable score for such recalls.
Plain-English summary
Akorn Inc. is recalling all lots of Rifampin Capsules USP 300 mg distributed nationwide in the USA and Puerto Rico, available in 30 and 60 count bottles. The FDA has classified this as a Class II recall due to Good Manufacturing Practice (GMP) deviations.
The firm ceased operations and could no longer conduct stability studies required to confirm the product maintains its safety and effectiveness throughout its shelf life. Stability testing is critical to ensure medications do not degrade and remain effective.
Patients taking Rifampin should contact their healthcare provider or pharmacist for guidance on whether to continue or discontinue use. Healthcare providers may consider whether alternative treatments are appropriate for affected patients.
The product was distributed nationwide in the USA and Puerto Rico and may remain in pharmacies and patients' homes. Consumers should not dispose of medication without consulting their pharmacist.
The recalled product
- Product
- Rifampin Capsules USP, 300 mg, packaged in a) 30 count bottles and b) 60 count bottles, Rx Only, Distributed by: Akorn Operating Company LLC, Gurnee, IL 60031. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug
- Hazard
- cgmp-deviation
- incomplete-stability-testing
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27